Department of Dermatovenerology, University Medical Centre Ljubljana, Gradiškova Ulica 10, SI-1000 Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Vrazov Trg 2, SI-1000 Ljubljana, Slovenia.
Int J Mol Sci. 2022 Jun 14;23(12):6648. doi: 10.3390/ijms23126648.
Psoriasis is a chronic systemic inflammatory disease. Due to systemic inflammation, it is associated with many comorbidities. Among them, cardiovascular diseases represent the most common causes of morbidity and mortality in this population. Therefore, physicians treating patients with psoriasis should keep in mind that, as important as the treatment of psoriasis, awareness of cardiovascular risk deserves additional attention. Thus, in parallel with psoriasis treatment, a cardiovascular risk assessment must also be performed and addressed accordingly. In addition to encouraging non-pharmacologic strategies for a healthy lifestyle, physicians should be familiar with different pharmacologic options that can target psoriasis and reduce cardiovascular risk. In the present article, we present the pathophysiological mechanisms of the psoriasis and cardiometabolic interplay, our view on the interaction of psoriasis and cardiovascular disease, review the atherosclerotic effect of therapeutic options used in psoriasis, and vice versa, i.e., what the effect of medications used in the prevention of atherosclerosis could be on psoriasis.
银屑病是一种慢性全身性炎症性疾病。由于全身炎症，它与许多合并症相关。其中，心血管疾病是该人群发病率和死亡率的最常见原因。因此，治疗银屑病的医生应牢记，与银屑病的治疗同样重要的是，对心血管风险的认识值得额外关注。因此，除了鼓励采用非药物策略来维持健康的生活方式外，医生还应熟悉针对银屑病和降低心血管风险的不同药物选择。在本文中，我们介绍了银屑病和心脏代谢相互作用的病理生理学机制，我们对银屑病和心血管疾病相互作用的看法，回顾了用于银屑病治疗的治疗方案的动脉粥样硬化作用，反之亦然，即用于预防动脉粥样硬化的药物对银屑病可能产生的影响。
